Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ximiteinib plus irinotecan in advanced esophageal squamous cell carcinoma
CTR20240381Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ximiteinib, irinotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Institute of Materia Medica. Started Mar 2024; status: active.
02
Drugs
ximiteinibirinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20240381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240381.